“Embedded in Lupin is a formula for growth which fuels creativity, performance and innovation”
It was Dr. Desh Bandhu Gupta’s vision and passion which helped him grow a small dream into a large company with a global footprint.
The most advanced pharmaceutical product development
Progressing towards the development of
Producing quality medicines in areas of
Producing high quality affordable
and accessible biologics
Mumbai, August 30, 2017: Pharma Major Lupin Limited (Lupin) announced that its Japanese subsidiary Kyowa Pharmaceutical Industry Co., Ltd. (headquarters: Yodogawa-ku, Osaka; President and Representative Director: Ray Tsunoda; hereinafter Kyowa) announced the listing of the NHI (National Health Insurance) drug price for Bipresso® (generic name: Quetiapine Fumarate) extended release 50mg and 150 mg tablets for the treatment of depressive symptoms associated with bipolar disorder.
NHI drug price:
71.00 Yen per 50mg tablet
188.60 Yen per 150mg tablet
Astellas Pharma Inc. (President and CEO: Yoshihiko Hatanaka; hereinafter Astellas) obtained approval for Bipresso® Extended Release Tablets on July 3, 2017. Bipresso® Extended Release Tablets contains the active ingredient quetiapine fumarate and is an extended-release tablet to be taken orally once a day. Earlier, Astellas had submitted an application to manufacture and sell Bipresso® extended-release 50mg and 150 mg tablets for the improvement of depressive symptoms associated with bipolar disorder following a development request from the Ministry of Health, Labour and Welfare’s Evaluation Committee of Unapproved or Off-Labeled Drugs with High Medical Need.
Based on the agreement between Astellas and Kyowa made in February 2017, Kyowa will distribute, sell and promote Bipresso® Extended-Release Tablets exclusively in Japan.
Dr. Fabrice Egros, chairman and representative director of Kyowa, remarked, “Today Kyowa is entering the CNS specialty field to serve high medical needs for patients suffering from severe diseases. Bipresso® Extended Release Tablets received its NHI price listing following PMDA approval last July based on a governmental advisory body request for its high medical need. It is estimated that hundreds of thousands patients are suffering from bipolar disorder in Japan.”
(*from Ministry of Health, Labour and Welfare’s homepage on bipolar disorder:http://www.mhlw.go.jp/kokoro/speciality/detail_bipolar.html)
Ray Tsunoda, president and representative director of Kyowa, added, “Up till now Kyowa primarily expanded its business in generics and enhanced branded AMEL CNS generics, covering 94% of the Psychiatric Institution nationwide. Last year, Kyowa reached an agreement with Shionogi & Co., Ltd. to transfer 21 long-listed drugs, with a large part of them being essential medicines. Now with this transaction with Astellas, Kyowa will be able to provide Bipresso® Extended Release Tablets, a new product that meets a high medical need. While continuing to offer a wide variety of generic drugs under the Kyowa AMEL brand, Kyowa is reinforcing its operations by emphasizing its expertise and speciality in CNS to provide generic, long-listed and new drugs in the CNS therapeutic area. Kyowa is working to bring Bipresso® Extended Release Tablets to market as soon as possible and promote its appropriate use effectively.”
Product Description of Bipresso® Extended Release Tablets, 50mg, 150mg
188.60 Yen per 150mg tablet
About Kyowa Pharma
Founded in 1954, Kyowa Pharmaceutical Industry Co., Ltd. (http://www.kyowayakuhin.co.jp/) develops, manufactures and sells branded and generic pharmaceutical products for patients in the Japanese market. With sales of 28.8 billion yen for the fiscal year ended March 2017, Kyowa is one of the fastest growing pharmaceutical companies in Japan. With a diverse product lineup that covers cardiovascular, gastroenterology and a wide variety of other segments, Kyowa has a particularly strong presence in the central nervous system/neurology space and covers 94% of the 1,400 psychiatric hospitals in Japan. In addition to its Kyowa AMEL brand franchise of high-quality generic drugs, Kyowa is reinforcing its operations by emphasizing its expertise and speciality in CNS to provide generic, long-listed and new drugs in the CNS therapeutic area.
Kyowa is a Japanese subsidiary of Lupin Limited.
About Lupin Limited
Lupin is an innovation led transnational pharmaceutical company developing and delivering a wide range of branded & generic formulations, biotechnology products and APIs globally. The Company is a significant player in the Cardiovascular, Diabetology, Asthma, Pediatric, CNS, GI, Anti-Infective and NSAID space and holds global leadership position in the Anti-TB segment.
Lupin is the 7th and 6th largest generics pharmaceutical company by market capitalization (June 30th, 2017, Bloomberg) and revenues (March 31st, 2017, Bloomberg) respectively. The Company is the 4th largest pharmaceutical player in the US by prescriptions (Quintiles IMS MAT March 2017); 2nd largest Indian pharmaceutical company by global revenues (March 31st, 2017, Bloomberg); 6th largest generic pharmaceutical player in Japan and 6th largest company in Indian Pharmaceutical Market (Quintiles IMS MAT June 2017). For the financial year ended 31st March, 2017, Lupin’s Consolidated sales and Net profit stood at Rs. 171,198 million (USD 2.55 billion) and Rs. 25,575 million (USD 381 million) respectively. Please visit http://www.lupin.com for more information. You could also follow us on Twitter – www.twitter.com/lupinlimited
CIN: L24100MH1983PLC029442 Registered Office: Lupin Ltd, 3rd Floor, Kalpataru Inspire, Off Western Express Highway, Santacruz (East), Mumbai 400 055.
For further information or queries please contact –
VP – Corporate Communications
Manager – Corporate Communications
Ph: +91-22-66402409 / 9167241531